CXCR4 and colorectal carcinoma: Conversely, treating patients with CRC for seven days with continuous infusion of the CXCR4 inhibitor AMD3100/Plerixafor induces an integrated immune response with enhanced intratumoral immune B and T cell responses as observed in paired biopsies of metastatic lesions (NCT02179970) [268], an immune response that is predictive of a clinical response to T cell checkpoint inhibition.